# Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML

> **NCT04676243** · PHASE3 · WITHDRAWN · sponsor: **University Hospital Heidelberg**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Quizartinib
- **DRUG:** Treatment according to Physician's Choice
- **DRUG:** Standard of Care Chemotherapy

## Key facts

- **NCT ID:** NCT04676243
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study turned out no longer feasible
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676243, "Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04676243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*